Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nu Holdings
NU
5
Liberty Latin America-A
LILA
CN Stock MarketDetailed Quotes
002370 Zhejiang Yatai Pharmaceutical
- 3.32
- -0.01-0.30%
Trading Apr 25 13:06 CST
2.48BMarket Cap72.17P/E (TTM)
3.40High3.30Low183.09KlotVolume3.34Open3.33Pre Close61.10MTurnover2.46%Turnover Ratio72.17P/E (Static)745.67MShares4.3852wk High2.61P/B2.48BFloat Cap2.2152wk Low3.66Limit Up745.67MShs Float22.10Historical High3.00Limit Down3.00%Amplitude2.21Historical Low--Dividend TTM3.34Avg Price97.70KlotAsk--Div YieldTTM100Lot Size84.11KlotBid
Zhejiang Yatai Pharmaceutical News
Asia Pacific Pharmaceutical: Summary of Non-operating Capital Utilization and Other Related Capital Transactions in 2024
Asia Pacific Pharmaceutical: Internal Control Audit Report
Asia Pacific Pharmaceutical: Announcement on changing the company\'s registered capital and amending the “Articles of Association”
Asia Pacific Pharmaceuticals: Announcement on Proposed Renewal of Accounting Firms
Asia Pacific Pharmaceutical: Special inspection opinions on the 2024 operating income deduction matters of Zhejiang Asia Pacific Pharmaceutical Co., Ltd.
Asia Pacific Pharmaceutical: Report on the Work of the Supervisory Committee 2024
Asia Pacific Pharmaceutical: Announcement on Using Idle Own Funds to Purchase Bank Wealth Management Products
Asia Pacific Pharmaceutical: 2024 Annual Audit Report
Asia Pacific Pharmaceutical: Special Instructions on the Use of Annual Funds Raised
Asia Pacific Pharmaceutical: Announcement of Supervisory Committee Resolutions
Asia Pacific Pharmaceutical: Notice on Accruing Credit Impairment Losses, Asset Impairment Losses and Asset Write-off
Asia Pacific Pharmaceutical: Annual Verification Report on the Use of Raised Funds
Asia Pacific Pharmaceutical: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2024 and the performance of supervisory duties
Asia Pacific Pharmaceuticals: Independent Director\'s Annual Debriefing Report
Asia Pacific Pharmaceuticals: Notice on Changes in Accounting Policies
Asia Pacific Pharmaceutical: Board\'s Special Opinion on Independent Directors\' Independence Assessment
Asia Pacific Pharmaceutical: Announcement on the Company\'s Application for a Comprehensive Credit Line from the Bank
Asia Pacific Pharmaceuticals: 2024 Annual Report Summary
Asia Pacific Pharmaceuticals: Articles of Association
Asia Pacific Pharmaceutical: Announcement of Board Resolutions
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs